Rote-Hand-Brief: Ocrevus (Ocrelizumab)

Paul-Ehrlich-Institut Version 1 original current

Imported from official source

Neues Risiko für arzneimittelbedingte Leberschäden und Empfehlung zur Überwachung der Leberfunktion vor und während der Behandlung

This version

Version
1 of 1
Recorded
October 08, 2026 07:32
Change
Initial
Content hash
96d827a0f32b8956e6ca4f3b63d0c062
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.